PFG Investments LLC Boosts Holdings in OPKO Health, Inc. (NASDAQ:OPK)

PFG Investments LLC boosted its stake in OPKO Health, Inc. (NASDAQ:OPK) by 10.4% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,061,090 shares of the biotechnology company’s stock after acquiring an additional 100,125 shares during the period. PFG Investments LLC owned 0.15% of OPKO Health worth $1,581,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Rubric Capital Management LP raised its holdings in shares of OPKO Health by 800.0% in the 2nd quarter. Rubric Capital Management LP now owns 44,422,304 shares of the biotechnology company’s stock worth $55,528,000 after purchasing an additional 39,486,490 shares during the period. Assenagon Asset Management S.A. increased its position in OPKO Health by 142.5% in the third quarter. Assenagon Asset Management S.A. now owns 1,490,992 shares of the biotechnology company’s stock worth $2,227,000 after buying an additional 876,272 shares during the last quarter. Y.D. More Investments Ltd bought a new stake in shares of OPKO Health in the second quarter valued at $1,840,000. AWM Investment Company Inc. lifted its position in shares of OPKO Health by 18.2% during the 1st quarter. AWM Investment Company Inc. now owns 1,300,000 shares of the biotechnology company’s stock valued at $1,560,000 after buying an additional 200,000 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. grew its stake in shares of OPKO Health by 11.4% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 776,020 shares of the biotechnology company’s stock worth $931,000 after acquiring an additional 79,525 shares during the period. 64.63% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at OPKO Health

In other news, major shareholder Opko Health, Inc. sold 88,839 shares of the business’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $33.50, for a total transaction of $2,976,106.50. Following the completion of the transaction, the insider now owns 2,984,564 shares of the company’s stock, valued at approximately $99,982,894. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold a total of 401,444 shares of company stock valued at $13,304,127 in the last 90 days. Corporate insiders own 47.26% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on OPK shares. StockNews.com upgraded OPKO Health to a “sell” rating in a research note on Saturday, July 27th. Barrington Research restated an “outperform” rating and set a $2.25 price target on shares of OPKO Health in a research note on Friday, September 20th. HC Wainwright reiterated a “buy” rating and issued a $3.00 price objective on shares of OPKO Health in a research note on Thursday, September 26th. Finally, Piper Sandler restated an “overweight” rating and set a $3.00 target price on shares of OPKO Health in a research report on Tuesday, September 17th.

OPKO Health Price Performance

Shares of NASDAQ:OPK opened at $1.42 on Friday. The company has a 50 day moving average of $1.54 and a 200 day moving average of $1.40. The company has a current ratio of 1.63, a quick ratio of 1.36 and a debt-to-equity ratio of 0.13. The stock has a market cap of $989.73 million, a P/E ratio of -4.06 and a beta of 1.63. OPKO Health, Inc. has a 12 month low of $0.85 and a 12 month high of $1.75.

OPKO Health (NASDAQ:OPK) last released its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($0.01) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.08. OPKO Health had a negative net margin of 33.79% and a negative return on equity of 17.67%. The firm had revenue of $182.20 million during the quarter, compared to analyst estimates of $184.70 million. During the same period in the previous year, the business earned ($0.03) EPS. The business’s revenue for the quarter was down 31.3% on a year-over-year basis. As a group, sell-side analysts forecast that OPKO Health, Inc. will post -0.29 EPS for the current fiscal year.

OPKO Health Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.